HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

Infection. 2016 Dec;44(6):789-792. doi: 10.1007/s15010-016-0937-4. Epub 2016 Aug 13.

Abstract

Purpose: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce.

Methods: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection).

Results: NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162-2.916).

Conclusions: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

Keywords: DAAs; HIV/HCV coinfected; Hepatitis C virus; RAVs.

MeSH terms

  • Antiviral Agents
  • Cohort Studies
  • Coinfection
  • Female
  • Genotype
  • HIV Infections / complications*
  • Hepacivirus / genetics*
  • Hepatitis C / complications*
  • Hepatitis C / virology*
  • Humans
  • Male
  • Middle Aged
  • Viral Nonstructural Proteins / genetics*

Substances

  • Antiviral Agents
  • NS3 protein, hepatitis C virus
  • Viral Nonstructural Proteins